GMI PEGylated Drugs Market

PEGylated Drugs Market Size, Industry Analysis Report, Regional Outlook Application Development Potential & Forecast, 2017 – 2024: Global Market Insights Inc. Pegylated Drugs Market can be used to treat chronic disorders like cancer. Cancer is of the leading cause of death and its prevalence is rising continuously. Binding of PEG with drugs facilitates its entry into the tumor cell and to give better therapeutic results. The demand for these drugs is high as it offers different advantages such as reduced degradation by metabolic enzymes, elimination of immunogenicity and increased residence in blood. It also enhances the solubility of drugs and reduces effects of proteolytic enzymes, thus improves the bioavailability. PEGylation refers to change in structure of protein by linking one or more polyethylene glycol (PEG) chains. It is easily soluble in organic and aqueous solutions and is non-toxic in nature. The chain binds to the drugs covalently and make it sterically stable. The polymer thus formed is non-toxic, non-antigenic, non-immunogenic, and highly water soluble. It further increases half-life of the drug and reduces dose frequency by preventing renal excretion of drugs. Increasing protein stability and circulating half-life, and increased R&D spending are some other impact rendering factors for industry. However, adverse drug reactions associated can impede market growth during forecast period. Attachment of PEG with drugs however, comes with certain limitations. In some cases, intravenous administration resulted in hypersensitivity reactions and blood clots. In other cases, it resulted in antibody production in body and has also shown hypersensitivity reactions when administered with laxatives. PEGylation products consists of different reagents including linkers, cross-linkers, and labels. Different reagents include AMINE, CARBOXYL, and CARBOXYL PEGylation. Drugs currently being used in the treatment of cancer, chronic kidney diseases, hepatitis, multiple sclerosis, hemophilia, and gastrointestinal disorders. Mircera, an erythropoiesis stimulating agent is approved by FDA for treatment of anemia associated with chronic renal failure. PEG-INTRON and PEGASYS are other FDA approved products for treatment of hepatitis C. 1 | Page